skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis

Review

(1173) Views  (307) Full article downloads

Authors: Douglas R Jeffery, Emily Poole Pharr

Published Date December 2010 Volume 2010:5 Pages 107 - 112
DOI: http://dx.doi.org/10.2147/CE.S9046

Douglas R Jeffery1, Emily Poole Pharr2
1MS Center at Advance Neurology, Advance, NC, USA; 2Department of Neurology, Wake Forest University Health Science, Winston-Salem, NC, USA

Abstract: Dalfampridine sustained-release (SR) is a time-release formulation of 4-aminopyridine, recently approved by the Food and Drug Administration to improve walking in patients with multiple sclerosis (MS). In Phase II trials, walking speed and lower extremity muscle strength was increased in patients with MS, but the increase in walking speed did not reach statistical significance. A responder analysis revealed that approximately 35% of treated patients had a statistically significant and clinically meaningful increase in walking speed. When treated responders were compared with treated nonresponders, walking speed significantly increased in the responder group, but not in the nonresponder or placebo groups. This result was duplicated in two larger Phase III trials. The optimal dose to maximize the risk–benefit ratio was 10 mg twice daily. Higher doses were associated with a greater risk of seizure, but no further improvement in walking speed or in the proportion of responders. Dalfampridine SR is eliminated by renal clearance and undergoes only limited metabolism (<10%). It is contraindicated in patients with moderate or severe renal insufficiency and in those with a history of seizures or epileptiform activity on electroencephalography. The development of time-released 4-aminopyridine represents a major advance in symptomatic therapy for MS.

Keywords: dalfampridine SR, multiple sclerosis, ambulation, walking speed, clinical trials, safety






Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
"Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Erratum
Optimization of single-walled carbon nanotube solubility by noncovalent PEGylation using experimental design methods
Erratum
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University